ABSTRACT
Introduction Data on burden of SARS-CoV-2 infections by age group and for different severity levels are lacking. We estimated the South African SARS-CoV-2 disease burden and severity, describing changes in the shape of the disease burden pyramid with successive waves.
Methods We estimated SARS-CoV-2 medically and non-medically attended illness stratified by severity (mild, severe non-fatal, and fatal) during the initial five waves, spanning 1 March 2020 through 13 August 2022. We utilised individual-level national surveillance, healthcare-utilisation and serosurvey data to calculate wave-specific hospitalisation-fatality (HFR) and infection-fatality ratios (IFR). We estimated wave-specific incidence rates per 100,000 population with 95% confidence intervals derived from bootstrapping the individual-level data.
Results On 13 August 2022, the estimated cumulative number of SARS-CoV-2 infections in South Africa was 105 million, of which 399,886 (0.38%) were severe non-fatal and 258,754 (0.25%) fatal. 29% of severe non-fatal illness and 55% of deaths occurred outside hospital. The highest burden of severe and fatal illness was during the Delta wave (wave 3), and the HFR across the initial three waves was similar (range 31%-34%). Although there were more infections during the Omicron BA.1 wave (wave 4), there was a substantial reduction in HFR (14%). Successive waves saw a reduction in the rate of increase in mortality and hospitalisations with increasing age.
Conclusions The substantial South African national burden of SARS-CoV-2 for the initial five waves contradicts the belief of minimal impact in Africa. A high proportion of severe non-fatal and fatal illness occurred outside of hospital, highlighting the importance of studies of health-seeking and vital registration systems to document the full burden of illness. Highest burden of severe illness and death was in the Delta wave. Following Omicron emergence severe illness reduced, and age-distribution for the incidence of medically attended severe non-fatal illness shifted to a J-shape, possibly reflecting the shift from widespread transmission to an endemic pattern.
What is already known on this topic?As SARS-CoV-2 spread globally, initial assumptions painted a bleak picture for Africa due to its existing challenges in healthcare service delivery, multimorbidity, poverty and lack of resources needed to fight the infection. The number of cases and deaths reported during the pandemic seemed to contradict these initial assumptions. South Africa recorded over 4 million laboratory-confirmed cases of COVID-19 during the first three years of the pandemic. However, it is estimated that only a tenth of the cases were diagnosed. With the lack of testing, inconsistent healthcare-seeking behaviour, changes in attack, reinfection and symptomatic rates, the true burden of SARS-CoV-2 across the different age groups and severity levels were largely unknown. Although real-time epidemiological data was crucial for informing intervention strategies throughout the pandemic, it is now essential to quantify and describe the evolution of the epidemiology over successive pandemic waves as more information was made available.
What this study adds?We found a high burden of severe illness and death in the first three waves of SARS-CoV-2, peaking in the third (Delta) wave. The emergence of the Omicron BA.1 variant was associated with very high rates of infection but substantial reductions in disease severity. Incidence of severe illness and hospitalisation fatality, generally increased with increasing age. Successive waves saw a reduction in the rate of the increase in mortality with increasing age and increases in hospitalisation fatality ratios in children below 5 years of age suggesting shift from the epidemic state to a J-shaped distribution in mortality, typical of seasonal respiratory viruses. Notably a high proportion of severe illness (29%) and death (55%) occurred outside hospital.
How this study might affect research, practice or policy?Our study provides insights into the changes in patterns of infection and disease following introduction of a novel pathogen into a susceptible population which may be useful for future pandemic planning. The high proportion of undiagnosed and unreported illness and the high proportion of severe illness and death occurring outside of the hospital suggest that strengthening of access to diagnosis and care is needed in our setting.
Competing Interest Statement
JP and LB received support for the current manuscript from Wellcome Trust and the South African Department of Science and Innovation (Centre of Excellence Grant). NW and CC received support from The US Centers for Disease control and prevention and CC furthermore received support from Wellcome Trust and South African Medical Research Council. JP has further received research grants from the Bill and Melinda Gates foundation and Stellenbosch University, NW from the Bill and Melinda Gates foundation, CC from PATH, the Bill and Melinda Gates foundation and Sanofi Pasteur, and SW from the Bill and Melinda Gates foundation, the US Centers for Disease control and prevention and the South African National Institute for Communicable Diseases. LB has undertaken contract research for the South African National Blood Services, the South African National Institute for Communicable Diseases, Department of Paediatrics and Child Health at Stellenbosch University (African Academy of Sciences/Bill and Melinda Gates Foundation grant) and University of Witwatersrand (Thuthuka grant). JP and LB has been paid consulting fees by the National Institute for Public Health and the Environment, The Netherland, and Department of Paediatrics and Child Health at Stellenbosch University, respectively. JP participated in a data safety monitoring or advisory board for the Medical Research council for global infectious disease analysis, Imperial college London. JK received support for attending meetings or travel from Fogarty International Center, National Institutes of Health, Bethesda, Maryland, Bill and Melinda Gates Foundation and University of Pittsburg, LB from Grand Challenges Africa, Science for Africa, World Society for Paediatric Infectious diseases, Global Womens Research Society and Department of Paediatrics and Child Health at Stellenbosch University; NW from the World Health Organisation and JP from the Bill and Melinda Gates Foundation. JK held a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid at the South African Field Epidemiology Training Programme Alumni Association. NMs institution has received funding from Pfizer for an unrelated research project. NM sits on the boards of the Wits Health Consortium (Pty) Ltd (an unpaid position) and the Setshaba Research Centre for which he is paid per board meeting. He has no other potential conflicts of interest. AvG has received funding from the US Centers for Disease control and prevention, SA Medical Research Council (SAMRC)/UKZN KRISP, CDC Atlanta and CDC SA (through AFENET), Africa PGI (through ASLM), Fleming Fund Regional Africa WGS (SEQAFRICA) and WHO AFRO. All other authors have no competing interests to declare.
Funding Statement
SACEMA (LB and JRCP) was supported by the South African Department of Science and Innovation and the National Research Foundation for the duration of this research (grant number 44895). NW obtained funding for the HUS from the South African Medical Research Council (Reference number SHIPNCD 76756), The Wellcome Trust and the United Kingdom Foreign, Commonwealth and Development Office (Grant no 221003/Z/20/Z) and United States Centers for Disease Control and Prevention (Grant number 5 U01IP001048-05-00).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Excess death data were provided in aggregate form; therefore, individual consent was not required. The Human Research Ethics Committee (Medical) at the University of the Witwatersrand (Johannesburg, South Africa) approved the DATCOV protocol as part of a national surveillance programme (M160667). Because COVID-19 is a notifiable disease, individual patient consent was waived. The PHIRST-C and HUS protocol were approved by the University of Witwatersrand, Johannesburg, South Africa, Human Research Ethics Committee (reference 150808 and M200862, respectively).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data for this analysis was obtained from several different sources. Requests for the underlying data should be made from the custodians of the data. Aggregated DATCOV data are available on request to the South African National Institute of Communicable Diseases (NICD). The data dictionary is available on request to the data custodian, Dr Waasila Jassat (waasilaj{at}genesis-analytics.com).
